U.S. FDA Approves an Additional Indication for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
RegulatoryapprovedCapvaxivePositive
AI Analysis
Summary
Merck announced FDA approval of an expanded indication for Capvaxive (pneumococcal 21-valent conjugate vaccine) for children and adolescents aged 2-17 at increased risk for pneumococcal disease. This label expansion represents a significant regulatory achievement for the vaccine portfolio.
Outcome Details
FDA approved an expanded indication for Capvaxive in children and adolescents aged 2 through 17 at increased risk for pneumococcal disease
Importance:8/10
Sentiment:
0.85
FDA approvallabel expansionvaccinespediatric indication
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 18, 2026 3:07 AM